Quintessence Biosciences is working to improve the lives of cancer patients by developing new drugs based on EVade Ribonuclease technologies.
Lead Candidate, QBI-139
A first in human Phase I trial of QBI-139 in cancer patients
with solid tumors enrolled patients at the University of Wisconsin
Comprehensive Cancer Center (UWCCC)
in Madison and The University of Texas M. D. Anderson Cancer Center in Houston, Texas.
Information about the trial can be found at www.clinicaltrials.gov
(Clinical Trials.gov Identifier: NCT00818831).
21-22 October 2014DLSS Entrepreneur Summit (Agenda) Quintessence Biosciences (QuintBio) will be attending the DLSS Summit in Milwaukee, Wisconsin.
3-5 November 2014BIOEurope (Agenda)
Quintessence Biosciences (QuintBio) will be meeting with potential development partners at the BIOEurope Partnering conference in Frankfurt Germany.
16-18 November 2014 Partnering for Cures (Program)
Quintessence Biosciences (QuintBio) will be meeting with potential development partners at the Partnering for Cures conference in New York City.